Pope Thaddeus Mason
Health Law Institute, Hamline University School of Law, Saint Paul, Minnesota, USA.
J Clin Ethics. 2013 Summer;24(2):156-67.
This issue's "legal briefing" column covers recent legal developments involving the Patient Self-Determination Act (PSDA). Enacted in the wake of the U.S. Supreme Court's Cruzan decision in 1990, the PSDA remains a seminal event in the development of U.S. bioethics public policy, but the PSDA has long been criticized as inadequate and ineffective. Finally, recent legislative and regulatory changes promise to revitalize and rejuvenate it. The PSDA has been the subject of recent articles in The Journal of clinical ethics.' I categorize new legal developments concerning the PSDA into the following eight sections: (1) Background and history (2) Rules and requirements (3) Criticism and challenges (4) Failed efforts to amend the PSDA (5) Personalize your Care Act of 2013 (6) New regulations (7) New regulatory guidance (8) Expanded enforcement.
本期的“法律简报”专栏涵盖了近期涉及《患者自主决定法案》(PSDA)的法律动态。该法案于1990年美国最高法院对克鲁赞案做出裁决后颁布,它在美国生物伦理公共政策的发展过程中依然是一个具有重大意义的事件,但长期以来一直被批评为不完善且无效。最终,近期的立法和监管变革有望使其重振活力。《临床伦理学杂志》近期发表了多篇关于PSDA的文章。我将有关PSDA的新法律动态分为以下八个部分:(1)背景与历史(2)规则与要求(3)批评与挑战(4)修订PSDA的失败尝试(5)2013年《个性化医疗法案》(6)新法规(7)新的监管指南(8)强化执法。